Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDK53C
|
|||
| Drug Name |
BTRX-335140
|
|||
| Synonyms |
CYM-53093; UNII-XK5ILZ28KI; XK5ILZ28KI; 2244614-14-8; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine; CHEMBL4592045; SCHEMBL20670520; GTPL10452; BTRX335140; BCP32121; CYM53093; BDBM50531908; compound 58 [PMID: 30707578]; HY-124754; CS-0087593; BTRX 335140; BTRX335140; CYM-53093; CYM 53093; CYM53093; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine; 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine; 4-Piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-N-(tetrahydro-2H-pyran-4-yl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2; ICD-9: 296.2, 296.3] | Phase 2 | [1] | |
| Company |
BlackThorn Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H32FN5O2
|
|||
| Canonical SMILES |
CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
|
|||
| InChI |
1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
|
|||
| InChIKey |
CQOJHAJWCDJEAT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2244614-14-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04221230) Study in Major Depressive Disorder With BTRX-335140 vs Placebo. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BlackThorn Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.